副鼻腔扁平上皮癌患者における術前化学療法へのセミプリマブ（REGN2810）追加の試験
鼻腔・副鼻腔扁平上皮癌におけるネオアジュバント化学療法にセミプリマブ（REGN2810）を併用するか否かの比較：無作為化第2相試験
This phase II trial compares the effect of chemotherapy (carboplatin and paclitaxel) with versus without cemiplimab given before surgery (neoadjuvant) in patients with sinonasal squamous cell cancer. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients with sinonasal squamous cell cancer is surgery followed by radiation therapy, with or without chemotherapy. Recently, some patients have also been treated with neoadjuvant chemotherapy before surgery. Adding cemiplimab to chemotherapy before surgery may be more effective at stopping the cancer from growing or spreading, compared to chemotherapy alone.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To assess whether neoadjuvant therapy (NAT) with cemiplimab (REGN2810)/carboplatin/paclitaxel (Arm 1) results in improved event free survival (EFS) compared to carboplatin/paclitaxel (Arm 2) in participants with sinonasal squamous cell carcinoma (SNSCC).
SECONDARY OBJECTIVES:
I. To compare objective response rate (ORR) between neoadjuvant cemiplimab (REGN2810)/carboplatin/paclitaxel (Arm 1) and neoadjuvant carboplatin/paclitaxel (Arm 2) and to historical standard of care (SOC) in participants with SNSCC.
II. To compare overall survival (OS) between neoadjuvant cemiplimab (REGN2810)/carboplatin/paclitaxel (Arm 1) and carboplatin/paclitaxel (Arm 2) and to historical SOC in participants with SNSCC.
III. To characterize toxicity with NAT in SNSCC. IV. To measure changes in T-cell clonality/diversity using ribonucleic acid (RNA) sequencing (RNAseq) and correlate with NAT response and EFS.
V. To evaluate organ preservation (orbital and skull base) rate with NAT in SNSCC.
CORRELATIVE OBJECTIVES:
I. To correlate human papillomavirus (HPV) status with ORR and OS after NAT. II. To correlate combined positive score (CPS) for PD-L1 expression with OS and EFS.
III. To measure the kinetics of circulating tumor DNA (ctDNA) pre- and post-NAT and correlate with ORR and OS after NAT.
IV. To correlate change in Sinonasal Morbidity Score with ORR and EFS after NAT.
V. To conduct DNA sequencing on pre-treatment tumor biopsies to determine whether features of the tumor genomic landscape are associated with response to NAT.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM 1:
NAT: Patients receive cemiplimab intravenously (IV) over 30 minutes on day 1 of each cycle, carboplatin IV over 30 minutes on day 1 of each cycle, and paclitaxel IV over 180 minutes on day 1 of each cycle. Cycles repeat every 21 days (3 weeks) for up to 2 cycles (6 weeks) in the absence of disease progression or unacceptable toxicity. At the discretion of the investigator, patients may alternatively receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes weekly during the 2, 3-week cycles. Up to 14 days after completion of NAT, patients are evaluated for response and proceed to definitive therapy.
DEFINITIVE THERAPY: Patients with complete response (CR) or partial response (PR) receive concurrent SOC chemoradiotherapy (CRT). Patients with stable disease (SD) or progressive disease (PD) undergo surgery within 6 weeks of completion of NAT followed by SOC adjuvant therapy.
ADJUVANT THERAPY: Within 3-4 weeks of NAT or 4-6 weeks of surgery, patients undergo radiation therapy (RT) once daily, 5 days per week for a total of 30 fractions over 6 weeks and receive cisplatin or carboplatin weekly during RT.
Patients also undergo magnetic resonance imaging (MRI), positron emission tomography (PET)/computed tomography (CT), CT, and collection of blood samples throughout the trial. Patients may undergo biopsy pre-treatment and/or on study.
ARM 2:
NAT: Patients receive carboplatin IV over 30 minutes on day 1 of each cycle and paclitaxel IV over 180 minutes on day 1 of each cycle. Cycles repeat every 21 days (3 weeks) for up to 2 cycles (6 weeks) in the absence of disease progression or unacceptable toxicity. At the discretion of the investigator, patients may alternatively receive carboplatin IV over 30 minutes and paclitaxel IV over 60 minutes weekly during the 2, 3-week cycles. Up to 14 days after completion of NAT, patients are evaluated for response and proceed to definitive therapy.
DEFINITIVE THERAPY: Patients with CR or PR receive concurrent SOC CRT. Patients with SD or PD undergo surgery within 6 weeks of completion of NAT followed by SOC adjuvant therapy.
ADJUVANT THERAPY: Within 4-6 weeks of surgery, patients undergo RT once daily, 5 days per week for a total of 30 fractions over 6 weeks and receive cisplatin or carboplatin weekly during RT.
Patients also undergo MRI, PET/CT, CT, and collection of blood samples throughout the trial. Patients may undergo biopsy pre-treatment and/or on study.
After completion of definitive therapy, patients are followed up at 3, 9, 15, 21, and 27 months and then every 12 months for an additional 3 years (5 years total follow up).
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Irvine、California、アメリカ、92612
- 募集
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
コンタクト：
- Site Public Contact
- 電話番号：877-827-8839
- メール：ucstudy@uci.edu
-
主任研究者：
- Edward Kuan
-
Los Angeles、California、アメリカ、90033
- 募集
- USC / Norris Comprehensive Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：323-865-0451
-
主任研究者：
- Jacob S. Thomas
-
Orange、California、アメリカ、92868
- 募集
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：877-827-8839
- メール：ucstudy@uci.edu
-
主任研究者：
- Edward Kuan
-
Sacramento、California、アメリカ、95817
- 募集
- University of California Davis Comprehensive Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：916-734-3089
-
主任研究者：
- Shiruyeh Schokrpur
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06520
- 募集
- Yale University
-
コンタクト：
- Site Public Contact
- 電話番号：203-785-5702
- メール：canceranswers@yale.edu
-
主任研究者：
- Aarti Bhatia
-
Trumbull、Connecticut、アメリカ、06611
- 募集
- Smilow Cancer Hospital Care Center-Trumbull
-
コンタクト：
- Site Public Contact
- 電話番号：203-785-5702
- メール：canceranswers@yale.edu
-
主任研究者：
- Aarti Bhatia
-
Waterbury、Connecticut、アメリカ、06708
- 募集
- Smilow Cancer Hospital-Waterbury Care Center
-
コンタクト：
- Site Public Contact
- 電話番号：203-785-5702
- メール：canceranswers@yale.edu
-
主任研究者：
- Aarti Bhatia
-
Waterford、Connecticut、アメリカ、06385
- 募集
- Smilow Cancer Hospital Care Center - Waterford
-
コンタクト：
- Site Public Contact
- 電話番号：203-785-5702
- メール：canceranswers@yale.edu
-
主任研究者：
- Aarti Bhatia
-
-
Florida
-
Ruskin、Florida、アメリカ、33570
- 募集
- Moffitt Cancer Center at SouthShore
-
コンタクト：
- Site Public Contact
- 電話番号：800-679-0775
- メール：ClinicalTrials@moffitt.org
-
主任研究者：
- Jimmy J. Caudell
-
Tampa、Florida、アメリカ、33607
- 募集
- Moffitt Cancer Center-International Plaza
-
コンタクト：
- Site Public Contact
- 電話番号：800-679-0775
- メール：ClinicalTrials@moffitt.org
-
主任研究者：
- Jimmy J. Caudell
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center - McKinley Campus
-
コンタクト：
- Site Public Contact
- 電話番号：800-679-0775
- メール：ClinicalTrials@moffitt.org
-
主任研究者：
- Jimmy J. Caudell
-
Tampa、Florida、アメリカ、33612
- 募集
- Moffitt Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：800-679-0775
- メール：ClinicalTrials@moffitt.org
-
主任研究者：
- Jimmy J. Caudell
-
Wesley Chapel、Florida、アメリカ、33544
- 募集
- Moffitt Cancer Center at Wesley Chapel
-
コンタクト：
- Site Public Contact
- 電話番号：800-679-0775
- メール：ClinicalTrials@moffitt.org
-
主任研究者：
- Jimmy J. Caudell
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30308
- 募集
- Emory University Hospital Midtown
-
コンタクト：
- Site Public Contact
- 電話番号：888-946-7447
-
主任研究者：
- Jose A. Monteiro de Oliveira Novaes
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- 募集
- University of Kentucky/Markey Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：859-257-3379
-
主任研究者：
- Susanne M. Arnold
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- 募集
- UNC Lineberger Comprehensive Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：877-668-0683
- メール：cancerclinicaltrials@med.unc.edu
-
主任研究者：
- Siddharth Sheth
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- 募集
- UPMC Hillman Cancer Center
-
コンタクト：
- Site Public Contact
- 電話番号：412-647-8073
-
主任研究者：
- Dan P. Zandberg
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- 募集
- University of Virginia Cancer Center
-
主任研究者：
- Varinder Kaur
-
コンタクト：
- Site Public Contact
- 電話番号：434-243-6303
- メール：uvacancertrials@hscmail.mcc.virginia.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must have histologically confirmed squamous cell carcinoma of sinonasal origin
-
Patients must have a T stage (T3, T4a, and select T4b) primary tumor according to American Joint Committee on Cancer (AJCC) 8th edition. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥ 2 cm) by chest x-ray or as ≥ 10 mm (≥ 1 cm) with CT scan, MRI, or calipers by clinical exam
-
No evidence of metastatic disease determined by pre-treatment imaging. Metastatic disease to neck nodes is considered locally advanced and therefore allowable. Patients with N0 and N1-3 disease will be eligible
-
Known HPV status (i.e., HPV negative, p16 immunohistochemistry [IHC] positive, high risk [HR]-HPV in situ hybridization [ISH] positive) from testing performed prior to referral. HPV status data (e.g., date of test, type of test [p16 IHC or HR-HPV ISH] and testing result) must be collected during enrollment. Patients who do not have this information available for collection will not be enrolled on this study
-
Age ≥ 18 years
- Because no dosing or adverse event data are currently available on the use of cemiplimab (REGN2810) in combination with carboplatin and paclitaxel in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)
-
Hemoglobin ≥ 8 g/dL (acceptable to reach via transfusion)
-
Absolute neutrophil count ≥ 1,500/mcL
-
Platelets ≥ 100,000/mcL
-
Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 × institutional ULN
-
Creatinine clearance ≥ 40 mL/min
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
-
Based on its mechanism of action, cemiplimab (REGN2810) can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. For this reason and because paclitaxel is a class D agent with the potential for teratogenic or abortifacient effects, women of childbearing potential (WCBP) and men should use highly effective contraception during treatment and for 6 months after the last dose of the study drugs. WCBP and men should avoid donating eggs/sperm during treatment and for 6 months after the last dose of the study drugs. Women should discontinue nursing during treatment and for 6 months after the last dose of the study drugs
-
Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
-
Prior to enrollment, verification of payment coverage by insurance (or other payment) for neoadjuvant paclitaxel and carboplatin chemotherapy must be obtained
Exclusion Criteria:
- Patients with unresectable disease
- Patients presenting with T3 disease without the need for maxillectomy and/or orbital invasion requiring orbital dissection/resection
- Patients who have had any previous systemic therapy to the index lesion in the past 12 months. This includes cemiplimab (REGN2810) and/or other immune modulating agents. Previous systemic therapy may alter or affect response
- Patients who had palliative RT (< 20 Gy) within 1 week prior to entering the study
- Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune-mediated adverse events (imAEs)
- History of pneumonitis within the last 5 years
- Patients who have not recovered from adverse events (AEs) due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to cemiplimab (REGN2810) or carboplatin and paclitaxel
- Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous
- Pregnant women are excluded from this study because of the increased risk of immune-mediated rejection of the developing fetus with cemiplimab (REGN2810). Men and WCBP who are not prepared to use highly effective contraception during and for 6 months after completion of treatment are excluded from this study
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：Arm 1 (cemiplimab, carboplatin, paclitaxel)
See Detailed Description. |
Given IV
他の名前：
Given IV
他の名前：
Undergo MRI
他の名前：
Undergo biopsy
他の名前：
Undergo collection of blood samples
他の名前：
Undergo PET/CT
他の名前：
Undergo radiation therapy
他の名前：
Undergo surgery
他の名前：
Given IV
他の名前：
Given carboplatin
他の名前：
Undergo SOC CRT
他の名前：
Given cisplatin
他の名前：
Undergo PET/CT and CT
他の名前：
|
|
アクティブコンパレータ：Arm 2 (carboplatin, paclitaxel)
See Detailed Description. |
Given IV
他の名前：
Given IV
他の名前：
Undergo MRI
他の名前：
Undergo biopsy
他の名前：
Undergo collection of blood samples
他の名前：
Undergo PET/CT
他の名前：
Undergo radiation therapy
他の名前：
Undergo surgery
他の名前：
Given carboplatin
他の名前：
Undergo SOC CRT
他の名前：
Given cisplatin
他の名前：
Undergo PET/CT and CT
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event free survival (EFS)
時間枠：From randomization to first occurrence of progression of disease or death, assessed up to 5 years
|
Progression will be assessed per Response Evaluation Criteria in Solid Tumors version 1.1. To evaluate EFS, survival functions will be computed using the Kaplan-Meier method and compared between groups using the stratified log-rank test. Adjustment for additional covariates will be performed using Cox proportional hazards regression analysis if numbers allow. |
From randomization to first occurrence of progression of disease or death, assessed up to 5 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR)
時間枠：Up to 5 years
|
ORR will be defined as complete response + partial response (≥ 30% decrease in tumor volume) per Response Evaluation Criteria in Solid Tumors version 1.1 criteria. ORR will be estimated with a 95% confidence interval using the exact Clopper Pearson method. The ORR will be compared between with neoadjuvant cemiplimab (REGN2810)/carboplatin/paclitaxel (Arm 1) to carboplatin/paclitaxel (Arm 2) using the Cochran-Mantel-Haenszel test, stratified by the same factors used for the primary endpoint. ORR for the aggregate study cohort (Arm 1 + Arm 2) will be compared to historical standard of care using the same analysis plan. |
Up to 5 years
|
|
Incidence of adverse events (AEs) associated with neoadjuvant therapy (NAT)
時間枠：Up to 5 years
|
Both acute toxicities and chronic toxicities will be graded by the treating investigator using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The frequency of participants experiencing a specific AE will be tabulated by dose level, cycle, seriousness, worst severity, timing of occurrence, outcome, and relationship to study drug. In addition, the number and percentage of participants experiencing a specific toxicity will be tabulated similarly. Accrual will be halted if excessive numbers of unacceptable toxicities are observed. This is defined as > 30% grade 4 treatment-related AEs, which are directly attributable to NAT. |
Up to 5 years
|
|
Changes in T-cell clonality/diversity
時間枠：Up to 5 years
|
The changes in T-cell clonality/diversity will be assessed using ribonucleic acid sequencing (RNAseq) and correlated with NAT response and EFS. RNAseq data will undergo quality control, alignment to the human reference genome, and transcript quantification using standard bioinformatics pipelines. T-cell receptor sequences will be reconstructed using tools such as MiXCR or TRUST4. Measures of T-cell clonality and diversity (e.g., Shannon entropy, clonality index) will be calculated. Changes in T-cell clonality/diversity pre- and post-treatment will be assessed using paired t-tests or Wilcoxon signed-rank tests. Associations with NAT response and EFS will be analyzed using logistic regression and Cox proportional hazards models, adjusting for relevant covariates. Multiple testing correction using the Benjamini-Hochberg method will be applied where appropriate. |
Up to 5 years
|
|
Organ preservation rates
時間枠：Up to 5 years
|
Organ preservation in the post-treatment setting is defined as physical and functional preservation of the organ. For example, orbital preservation would imply maintenance of the entirety of the orbit and preservation of vision and motion. Orbital preservation rates will be summarized using descriptive statistics such as mean, standard deviation, median, and range. At the time of enrollment the treating team, with the guidance of the surgical team, will indicate what major anatomic locations would have to be resected if the patient elected initial primary surgical therapy (palate, orbit, and/or skull base). This prospective information will allow concrete subsequent secondary analyses of organ preservation rates without the bias of outcome or recall. |
Up to 5 years
|
|
Overall survival (OS)
時間枠：From the start of NAT to death, assessed up to 5 years
|
The Kaplan-Meier method will be used to estimate OS and 95% confidence intervals will be reported. OS for the aggregate study cohort (Arm 1 + Arm 2) will be compared to historical standard of care using the same analysis plan. |
From the start of NAT to death, assessed up to 5 years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
OS
時間枠：From the start of NAT to death, assessed up to 5 years
|
Will correlate human papillomavirus status, combined positive score for PD-L1 expression, and circulating tumor deoxyribonucleic acid (ctDNA) with OS. |
From the start of NAT to death, assessed up to 5 years
|
|
EFS
時間枠：From randomization to first occurrence of progression of disease or death, assessed up to 5 years
|
Will correlate human papillomavirus status, combined positive score for PD-L1 expression, and ctDNA with EFS. |
From randomization to first occurrence of progression of disease or death, assessed up to 5 years
|
|
NAT response rates
時間枠：Up to 5 years
|
Will correlate human papillomavirus status, combined positive score for PD-L1 expression, and ctDNA with NAT response rates. |
Up to 5 years
|
|
ctDNA
時間枠：At pre-treatment, in weeks 7-8 (post-NAT visit), and at 3 months following definitive treatment
|
ctDNA will be measured at pre-defined timepoints. Sequencing using whole exome sequencing will be conducted on pre-treatment tissue. |
At pre-treatment, in weeks 7-8 (post-NAT visit), and at 3 months following definitive treatment
|
協力者と研究者
捜査官
- 主任研究者：Siddharth Sheth、Ohio State University Comprehensive Cancer Center LAO
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 有機化学物質
- 調査手法
- 治療
- 臨床検査技術
- 診断技術と手順
- 診断
- 薬物療法
- 細胞学的技術
- 細胞診断
- 炭化水素
- シクロパラフィン
- 炭化水素、環状
- 炭化水素、周期的
- テルペン
- 物理現象
- 無機化学物質
- 塩素化合物
- 窒素化合物
- 調整錯体
- タキソイド
- シクロデカン
- Diterpenes
- 要素
- 金属
- ヘルスケアの経済学と組織
- 診断技術、外科的
- 化学技術、分析
- スペクトル分析
- 金属、重い
- プラチナ化合物
- 遷移要素
- 組み合わせたモダリティ療法
- 経済
- カルボプラチン
- パクリタキセル
- シスプラチン
- クエン酸1,2-ジアミノシクロヘキサン白金II
- 放射線療法
- 放射線
- 生検
- 標本処理
- 磁気共鳴分光法
- 外科的処置、手術
- 白金
- 化学放射線療法
- cemiplimab
- 税金
その他の研究ID番号
- NCI-2025-09016
- UM1CA186712 (米国 NIH グラント/契約)
- 10721 (その他の識別子：CTEP)
- NCI-2025-09016 (レジストリ識別子：CTRP (Clinical Trial Reporting Program))
- 10721 (その他の識別子：Ohio State University Comprehensive Cancer Center LAO)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。